Literature DB >> 18756039

The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia.

Toshitsugu Ishikawa1, Kyoichi Mizuno, Noriaki Nakaya, Yasuo Ohashi, Naoko Tajima, Toshio Kushiro, Tamio Teramoto, Shinichiro Uchiyama, Haruo Nakamura.   

Abstract

BACKGROUND: Several epidemiologic studies in Japan have shown the risk factors for coronary heart disease (CHD) in the general population. The present analysis determined the risk factors for CHD in the MEGA Study, a large primary prevention trial with pravastatin in Japanese with hypercholesterolemia. METHODS AND
RESULTS: The relationship between each baseline characteristic and the risk of CHD for the 5-year study period were evaluated using the Cox proportional hazard model. The multivariable predictors of CHD were sex, age, high-density lipoprotein-cholesterol (HDL-C), diabetes mellitus (DM), hypertension (HT), and history of smoking. Serum total and low-density lipoprotein-cholesterol were not independent risk factors for CHD in the current analysis. In addition, the effect of pravastatin was evaluated by subgroups in each risk factor using the interaction in a Cox model. Diet plus pravastatin treatment reduced CHD risk by 14-43% compared with diet alone, regardless of the presence or absence of risk factors.
CONCLUSIONS: The risk factors for CHD were sex, age, DM, HT, smoking, and low HDL-C in the MEGA Study. The pravastatin treatment was effective for reducing the risk of CHD, regardless of the presence of risk factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756039     DOI: 10.1253/circj.cj-08-0095

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

1.  Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).

Authors:  Noriaki Nakaya; Kyoichi Mizuno; Yasuo Ohashi; Tamio Teramoto; Shinji Yokoyama; Katsumi Hirahara; Masahiro Mizutani; Haruo Nakamura
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 2.  Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.

Authors:  Alan C Kwan; Konstantinos N Aronis; Veit Sandfort; Roger S Blumenthal; David A Bluemke
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-07-06

3.  Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.

Authors:  Samia Mora; Nanette K Wenger; David A Demicco; Andrei Breazna; S Matthijs Boekholdt; Benoit J Arsenault; Prakash Deedwania; John J P Kastelein; David D Waters
Journal:  Circulation       Date:  2012-03-29       Impact factor: 29.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.